- ISIN
- US04335A1051
- CUSIP
- 04335A105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 27, 2018
Highlights
- Market Cap
- $495.36M
- Enterprise Value
- $418.26M
- EPS (TTM)
- -$3.22
- Total Revenue (TTM)
- $89.40M
- Gross Profit (TTM)
- $72.60M
- EBITDA (TTM)
- -$233.90M
- Year Range
- $6.06 - $14.51
- Target Price
- $13.00
- ROA (TTM)
- -34.18%
- ROE (TTM)
- -57.21%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ARVN Performance Chart
Arvinas, Inc. (ARVN) is down 34.7% since the beginning of the year. At $8 per share, ARVN is trading 46.7% below its 52-week high of $15. Investors who bought $1,000 worth of ARVN shares 5 years ago would now be looking at an investment worth $102.
Loading charts...
Returns By Period
Arvinas, Inc. (ARVN) has returned -34.74% so far this year and 4.03% over the past 12 months.
Arvinas, Inc.
- 1D
- 0.91%
- 1M
- -14.85%
- YTD
- -34.74%
- 6M
- -37.18%
- 1Y
- 4.03%
- 3Y*
- -32.77%
- 5Y*
- -36.67%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ARVN Monthly Returns History
Based on dividend-adjusted daily data since Sep 27, 2018, ARVN's average daily return is +0.07%, while the average monthly return is +2.41%. At this rate, an investment would double in approximately 2.4 years.
Historically, 48% of months were positive and 52% were negative. The best month was Dec 2020 with a return of +251.0%, while the worst month was Mar 2025 at -60.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.
On a daily basis, ARVN closed higher 48% of trading days. The best single day was Dec 14, 2020 with a return of +95.1%, while the worst single day was Mar 11, 2025 at -52.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.82% | -0.82% | -20.12% | -6.60% | -9.29% | -13.81% | -34.74% | ||||||
| 2025 | -8.14% | 0.51% | -60.34% | 37.04% | -25.16% | 2.22% | 1.09% | 3.90% | 10.22% | 19.01% | 24.11% | -5.76% | -38.13% |
| 2024 | 0.83% | 10.80% | -10.22% | -23.04% | 4.31% | -19.67% | 3.34% | -4.91% | -5.85% | 7.31% | 1.10% | -28.26% | -53.43% |
| 2023 | -4.21% | -6.47% | -10.86% | -4.06% | -16.71% | 13.70% | -0.40% | 14.12% | -30.38% | -17.92% | 36.29% | 87.35% | 20.32% |
| 2022 | -12.97% | -9.34% | 3.84% | -18.32% | -24.16% | 0.96% | 26.18% | -20.28% | 5.08% | 11.73% | -17.44% | -16.64% | -58.35% |
| 2021 | -11.17% | 3.79% | -15.58% | 4.30% | 5.51% | 5.86% | 31.30% | -14.73% | -4.67% | 5.35% | -12.67% | 8.64% | -3.29% |
Benchmark Metrics
Arvinas, Inc. has an annualized alpha of -1.12%, beta of 1.23, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since September 27, 2018.
- This stock participated in 182.65% of S&P 500 Index downside but only 118.97% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -1.12%
- Beta
- 1.23
- R²
- 0.10
- Upside Capture
- 118.97%
- Downside Capture
- 182.65%
Return for Risk
Risk / Return Rank
ARVN ranks 44 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Arvinas, Inc. (ARVN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ARVN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.96 | ||
| Sortino ratioReturn per unit of downside risk | -2.24 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 1.37 | -0.30 |
| Calmar ratioReturn relative to maximum drawdown | 0.08 | 2.78 | -2.70 |
| Martin ratioReturn relative to average drawdown | 0.23 | 12.44 | -12.21 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Arvinas, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Arvinas, Inc. was 94.37%, occurring on May 14, 2025. The portfolio has not yet recovered.
The current Arvinas, Inc. drawdown is 92.82%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -94.37%May 2025 | 3y 9mo | — | 4y 10moJul 2021 - now |
2020 bear market2020 | -64.42%Oct 2020 | 5mo 12d | 1mo 24d | 7mo 6dMay 2020 - Dec 2020 |
Rate-hike selloffLate 2018 | -46.71%Dec 2018 | 2mo 28d | 1mo 19d | 4mo 17dSep 2018 - Feb 2019 |
2019 bear market2019 | -44.26%Oct 2019 | 2mo 21d | 26d | 3mo 17dJul 2019 - Nov 2019 |
COVID crash2020 | -39.45%Mar 2020 | 1mo 8d | 1mo 12d | 2mo 20dFeb 2020 - Apr 2020 |
Drawdown Indicators
| ARVN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.37% | -56.78% | -37.59% |
Max Drawdown (1Y)Largest decline over 1 year | -49.53% | -9.10% | -40.43% |
Max Drawdown (3Y)Largest decline over 3 years | -88.40% | -18.90% | -69.50% |
Max Drawdown (5Y)Largest decline over 5 years | -94.37% | -25.43% | -68.94% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -92.82% | -1.80% | -91.02% |
Average DrawdownAverage peak-to-trough decline | -52.12% | -10.71% | -41.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.70% | 2.03% | +15.67% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Arvinas, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Arvinas, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ARVN relative to other companies in the Biotechnology industry. Currently, ARVN has a P/S ratio of 5.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ARVN in comparison with other companies in the Biotechnology industry. Currently, ARVN has a P/B value of 1.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ARVN
Add Arvinas, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ARVN